Where do MNEs Expand Production: Location Choices of the Pharmaceutical Industry in Europe after 1992

Frances Ruane and Xiaoheng Zhang ()
Additional contact information
Xiaoheng Zhang: The Institute for International Integration Studies, Trinity College Dublin

No WP211, Papers from Economic and Social Research Institute (ESRI)

Abstract: Differences in regulations, technical standards and national medical cultures across EU member states created a highly segmented pharmaceutical market in Europe prior to the implementation of the Single Market Programme. The subsequent reduction in non-tariff barriers to trade would be expected to have an impact on where pharmaceutical multinationals locate production within the EU. Using discrete-choice models, we study the determinants of multinationals? location choices in terms of expanded production at existing facilities. Our results support the findings of New Economic Geography models that predict reduced rather than increased agglomeration in the face of trade-cost reductions.

Keywords: Economic geographic; location choice; discrete choice models; European integration; FDI (search for similar items in EconPapers)
JEL-codes: F15 F23 R12 (search for similar items in EconPapers)
Pages: 36 pages
Date: 2007-10
New Economics Papers: this item is included in nep-dcm, nep-int and nep-ure
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.esri.ie/pubs/WP211.pdf First version, 2007 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:esr:wpaper:wp211

Access Statistics for this paper

More papers in Papers from Economic and Social Research Institute (ESRI) Contact information at EDIRC.
Bibliographic data for series maintained by Sarah Burns ().